Maximus, Inc. (MMS) is a business process services provider that administers health and human services programs for governments. Coverage of the stock is unusually thin, with only a handful of active sell-side ratings. Reviewing current, attributable targets yields three: BTIG reiterated a Buy with a $100 target in July 2026; Raymond James (analyst Brian Gesuale) maintains an Outperform rating with a $95 target, raised from $90 in January 2026; and Stifel carries a $102 target. These three average roughly $99, which rounds to a central target of $100.
All three are constructive ratings, but that agreement partly reflects the small sample rather than a broad consensus. Because a couple of data aggregators include older or poorly attributed figures, reported ranges can vary widely — some show a $75-to-$110 band. Investors should treat the $100 figure as a calculated average of the current named targets, not as an official published consensus.
Shares of MMS closed near $64.71 in mid-November 2026, with a 52-week range of roughly $51 to $100. Reaching the $100 central target implies about 55% upside — a very large move. Notably, the stock already traded near that level within the past year, having touched a 52-week high around $100 before retreating roughly 35%. The path back to $100 therefore looks less like breaking into uncharted territory and more like reclaiming a prior high after a significant de-rating.
The company's fundamentals remain solid by valuation standards. Trailing twelve-month revenue is about $5.25 billion, net income roughly $371 million, and diluted EPS (earnings per share) near $6.76. The stock trades at a trailing P/E (price-to-earnings ratio) near 9.6 and a forward P/E near 7.8, well below the broader market. Management narrowed fiscal 2026 revenue guidance to roughly $5.2 billion to $5.35 billion, partly reflecting a divested U.S. services business, which has kept top-line expectations tempered even as profitability improves.
The $100 level is the most important reference point: it is both the psychological round number and the stock's 52-week high, acting as durable resistance. On the downside, the $51-to-$55 zone marks the 52-week low and a meaningful support area. The stock's roughly 35% decline from its high, combined with a beta below 1, indicates lower volatility than the broader market, but the distance back to $100 means any recovery would need sustained, multi-quarter confirmation rather than a single catalyst.
Analyst price targets typically reflect a roughly 12-month research horizon, though the thin coverage here means individual timelines may differ. The most important near-term events are the fiscal fourth-quarter earnings report (scheduled around late November 2026), management's fiscal 2027 guidance, and any analyst target revisions that follow. Investors should also watch federal budget developments, new contract announcements, and continued progress on margins and buybacks.
For traders who want a more dynamic view than a static 12-month price target, Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help users discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For those following MMS, it offers a complementary, data-driven way to track momentum alongside fundamental research.
The $100 central target is a calculated average of three current analyst targets — not a guarantee. It implies roughly 55% upside from the mid-$64 price, a very large move that would effectively reclaim the stock's 52-week high. The strongest supports are an inexpensive valuation, robust free cash flow, aggressive buybacks, dividend growth, and a healthy pipeline of government contracts. The principal obstacles are federal spending uncertainty, tempered revenue growth after a divestiture, and the stock's recent failure to hold elevated levels. With coverage thin and the range narrow, investors should focus on the upcoming earnings report, fiscal 2027 guidance, and any analyst revisions before drawing conclusions about the path toward $100.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MMS has been loosely correlated with ICFI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MMS jumps, then ICFI could also see price increases.
| Ticker / NAME | Correlation To MMS | 1D Price Change % | ||
|---|---|---|---|---|
| MMS | 100% | -5.00% | ||
| ICFI - MMS | 44% Loosely correlated | -1.94% | ||
| TRI - MMS | 44% Loosely correlated | -3.23% | ||
| BRC - MMS | 42% Loosely correlated | -1.98% | ||
| RELX - MMS | 40% Loosely correlated | -0.49% | ||
| BAH - MMS | 39% Loosely correlated | -1.67% | ||
More | ||||
| Ticker / NAME | Correlation To MMS | 1D Price Change % |
|---|---|---|
| MMS | 100% | -5.00% |
| Office Equipment/Supplies industry (45 stocks) | -2% Poorly correlated | +196.02% |
| Producer Manufacturing industry (346 stocks) | -4% Poorly correlated | +20.74% |